NCT05325099View on ClinicalTrials.gov

Demethylating Agent Azacitidine on Prevention of Acute Kidney Injury-chronic Kidney Disease Continuum

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 18, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

May 31, 2026

Conditions
Acute Kidney Disease
Interventions
DRUG

Azacitidine

azacitidine (Vidaza) 1mg/BW(kg) (subcutaneous injection) QOD x 3 times

DRUG

Placebo

Placebo (subcutaneous injection) QOD x 3 times

Trial Locations (1)

116

RECRUITING

Yu Hsiang Chou, Taipei

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER